Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide in Obesity (STEP 1)
NCT03548935Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2018
- Primary completion
- Mar 2020
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial in obesity and Overweight comparing Semaglutide 2.4 mg with Placebo (2 arms). Primary endpoints: Change in Body Weight (%) at 68 weeks and Participants Who Achieve 5 or More Percent Body Weight Reduction at 68 weeks. Started Jun 2018; status: completed.
02
Drugs
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT03548935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03548935.